Background: Acute and chronic myeloid leukemia are initiated and sustained by a small, self-renewing population of leukemic stem cells, which produce progeny of a heterogeneous population of progenitor cells. CXCL12, a chemokine abundantly produced by the bone marrow microenvironment, and its receptor CXCR4 have crucial roles in malignant cell trafficking. We set out to determine the CXCL12 gene polymorphism at codon G801A and evaluate its influence on malignant cell dissemination and tissue infiltration in myeloid leukemias. Methods: Genotyping for CXCL12 was done by restriction PCR-RFLP for 48 myeloid leukemia patients: 38 de novo AML and 10 CML. Fifty age and gender matched volunteers were evaluated as controls. Results: Regarding AML patients, the frequency of wild genotype was 50% and the heterozygous genotype was 50%. In CML patients, the frequency of wild genotype was 30% while the heterozygous genotype was 70%. In the control group, 57.2% had wild genotype while 42.8% had heterozygous genotype with no significant difference detected between myeloid leukemia patients and the control group. There was a statistically insignificant association between wild and heterozygous genotypes regarding clinical, laboratory data and extramedullary dissemination. Conclusions: CXCL12 polymorphism is not associated with either increased myeloid leukemia risk or extramedullary blast dissemination. (Clin. Lab. 2014;60:735-741.
INTRODUCTION
Myeloid leukemia (ML) is a potentially fatal hematological disease characterized by the production of abnormal myeloid blood cells that accumulate both in bone marrow and peripheral blood. Chronic (CML) and acute (AML) forms have been described which differ in their biology, and consequently, in their clinical presentation, treatment, and outcome. Both CML and AML arise from the clonal expansion of a transformed primitive hematopoietic cell, which gives rise to progeny with functional advantages over normal hematopoietic cells. Different genetic alterations have been identified in ML, such as the BCR-ABL gene and its product, in CML, and several molecular abnormalities in AML; it is noteworthy that many of such alterations have clinical significance [1] . Stromal cell derived factor-1 (SDF-1/CXCL12) is a 'homeostatic' chemokine that is constitutively secreted by marrow stromal cells [2] . CXCL12 signals through CXCR4 that is broadly expressed by normal and malignant cells of hematopoietic and non-hematopoietic lineage [3] . Chemokine receptors are characterized by their ability to induce directional migration of cells towards a gradient of a chemotactic cytokine (chemotaxis) [4] . CXCL12 regulates the homing and retention of hematopoietic progenitor cells in the marrow microenvironment [5] [6] [7] . Hematopoietic stem cells (HSC) migrate to CXCL12 [8] which is a prerequisite for the retention and maintenance of HSC in distinct stromal cell niches and the marrow-specific homing of circulating HSC [5, _____________________________________________ Manuscript accepted June 30, 2013 9,10]. The SDF-1/CXCR4 axis is involved in the trafficking of malignant cells [11] and signaling in many cancer cells, including those of solid tumors and hematological malignancies. CXCR4 and its ligand SDF-1 were shown to have an important role in breast, prostate, ovarian, and sympathetic nervous system cancer metastasis [12] [13] [14] [15] [16] . Limited information is available with regard to the biological and clinical importance of the locomotion of leukemia cells. Blast propagation to peripheral blood and extramedullary tissue may resemble mobilization of normal HSC. The granulocyte colony-stimulating factor-induced mobilization process is associated with a decrease in medullary levels of SDF-1 and up-regulation of CXCR4 [17] . The aim of the present work is to determine the CXCL12 coding gene polymorphism at codon G801A in the 3' untranslated region and evaluate its influence on malignant cell dissemination and tissue infiltration in acute and chronic myeloid leukemia.
MATERIALS AND METHODS

Study population
This study comprised 38 de-novo AML and 10 de-novo CML patients as well as 40 age and gender matched healthy volunteers as a control group. Cases were selected from Kasr El-Aini Teaching Hospital, Cairo University, Egypt. There were 26 males and 22 females. Their ages ranged from 17 to 68 years with a mean age of 37.42 ± 15.88 years. The research protocol was approved by the research Ethics Committee of the Departments of Clinical Pathology and Medical Oncology, Cairo University. Diagnosis of AML was based on morphological, immunophenotyping, and cytochemical criteria of the French-American-British (FAB) system [18, 19] . CML patients had hematological and laboratory criteria for diagnosis.
DNA extraction and genotyping
Genomic DNA extraction from peripheral blood leucocytes was done using a genomic DNA purification Kit (Fermentas, US) following the manufacturer's instructions. DNA samples were routinely stored at -20°C. Genotyping of CXCL12 G801A polymorphism was determined using a PCR-based restriction fragment length polymorphism (RFLP) method [20] . The forward primer used was 5'CAG TCA ACC TGG GCA AAG CC 3', whereas the reverse primer was 5'CCT GAC AGT CCT TTT GCG GG 3'. The PCR reaction was performed in a total volume of 25 μL containing 3 μL genomic DNA, 12.5 μL 2X Dream Taq Green PCR Master Mix, 1 μL of each forward and reverse primers (10 pmol) (Fermentas, Lithuania). PCR conditions were 94°C for 5 minutes, followed by 35 cycles of 94°C for 1 minute, 60°C for 1 minute and 72°C for 1 minute. The final extension was at 72°C for 10 minutes. The amplified PCR product (293 bp) was digested by the restriction enzyme Hpa II (Fermentas, USA). The DNA fragments were electrophoresed through a 2% agarose gel and stained with ethidium bromide. The GG allele produced two fragments (193 and 100 bp). The AA allele produced a single 293 bp band. The heterozygous genotype produced three bands (293, 193, and 100 bp).
Statistical Analysis
The data were analyzed using the Statistical Package for Social Science (SPSS) program version 17. Numerical data were summarized as mean and standard deviation or median and range as appropriate. Parametric data was analyzed using Student's t-test for two independent samples. A non parametric test (Mann Whitney U test) was used for the analysis of quantitative data. The chi square test and Fisher's exact test were used for analysis of qualitative data (Fisher's exact test was used when > 20% of variables were < 5 or when one variable was < 1). Logistic regression was used for calculation of odds ratio (OR) with 95% confidence interval (CI) for risk estimation. A p-value < 0.05 was considered significant.
RESULTS
The clinical and laboratory characteristics of AML patients are presented in Table 1 . The frequency of the studied genes among myeloid leukemia patients and controls are presented in Table 2 . Twenty-two leukemia patients (45.8%) had (G/G) wild genotype and 26 patients (54.2%) had (GA) heterozygous genotype. In the control group, 23 individuals (57.5%) had (G/G) genotype and 17 individuals (42.5%) had (GA) genotype. Statistical comparison between myeloid leukemia patients and controls regarding CXCL12 polymorphism revealed no significant difference (p = 0.267). Nineteen AML patients (50%) had (G/G) wild genotype and 19 patients (50%) had (GA) heterozygous genotype with no significant difference found between AML patients and controls (p = 0.507). Three CML patients (30%) had (G/G) wild genotype and 7 patients (70%) had a (GA) heterozygous genotype with no significant difference found between CML patients and controls (p = 0.164). Further analysis of the influence of the studied genetic polymorphism on the clinical and laboratory characteristics of the patients revealed no statistically significant difference between the CXCL12 (G/G) genotype and (GA) genotype carriers in AML and CML patients regarding demographic data: age, gender, clinical data including anemic manifestations, fever, bleeding tendency, hepatomegaly, splenomegaly, and lymphadenopathy, nor in laboratory data including hemoglobin level, total leucocyte count (TLC), platelets count, peripheral blood (PB) and bone marrow (BM) blast%, and FAB subtypes. However, organomegaly was slightly higher in CML patients carrying the variant allele (Table 3) . 
DISCUSSION
Acute myeloid leukemia is characterized by uncontrolled proliferation of myeloid progenitors within the bone marrow arrested in their maturation process. In contrast to normal hematopoiesis, it is usually associated with egress of immature cells from the bone marrow into the circulation before anchoring in extramedullar locations. Peripheral blood blast (PBB) counts and the number of extramedullar tumor sites are extremely variable from one patient to another and depend in part on AML subtype [21] . Chronic myelogenous leukemia is a malignant myeloproliferative disorder that originates from a pluripotent stem cell expressing the BCR-ABL oncogene. It is characterized by an abnormal release of the expanded, malignant stem cell clone from the bone marrow into circulation. The BCR-ABL oncogene is known to transduce its oncogenic signals through several pathways, which are then constitutively activated in a leukemic cell [22] . Several genetic polymorphisms have been identified as risk factors for leukemia by meta-analyses [23] [24] [25] . Nevertheless, despite the importance of genetic factors, only a few gene polymorphisms associated with leukemia susceptibility have been identified so far [26] . Attention has been focused on new molecular targets for therapy and biological markers of prognosis of myeloid leukemia. One of these is the CXC chemokine receptor 4 (CXCR4) which is one of chemokine receptors defined by their ability to induce cell migration toward a chemotactic cytokine gradient (chemotaxis). The CXCL12-CXCR4 axis is essential for the migration of normal cells to the bone marrow microenvironment. Also this axis appears to play a role in metastatic spread of neoplasms of both hematopoietic and solid tumors [27] .
The aim of the present work is to determine the CXCL12 coding gene polymorphism at codon G801A and evaluate its influence on malignant cell dissemination and tissue infiltration in acute and chronic myeloid leukemia. Regarding CXCL12 polymorphism in AML patients, the frequency of the wild genotype (G/G) was 50% and the heterozygous genotype (G/A) was 50%. Our results are in accordance with the studies of Dommange et al., Ponziani et al., and Abd El-Rahman et al. They found that the frequency of the wild genotype among AML patients was 56.9%, 57%, and 54.8%, respectively, while for the heterozygous genotype the frequency was 33.8%, 36%, and 45.2%, respectively [21, 28, 29] . Regarding CML patients, the frequency of the A allele (70%) was similar to De Oliveria et al. (60%) ; however, no statistical difference was found in the comparison to the control group [20] .
In the control group, 57.2% had wild (G/G) genotype while 42.8% had heterozygous (A/G) genotype. Our results were nearly similar to the study conducted by De Oliveria et al. and Gerli et al. [20, 30] who found that 65% and 61%, respectively, of their control groups had the wild (G/G) genotype while 35% and 39% had the heterozygous genotype (A/G). On other hand, our results were different from Abd El-Rahman et al. [29] as 82.9% of their control group had wild genotype (G/G) while 17.1% had heterozygous genotype (A/G). There was no statistical significance between acute myeloid leukemia patients and the control group regarding CXCL12 polymorphism. This was in accordance to Dommange et al. [21] . Regarding CML patients, the difference between patients and the control group did not reach a significant level compared to De Oliveria et al. [20] . This difference may be due to their large sample size regarding patients and control group. [28, 29] . On the contrary, Dommange et al. [21] found that the CXCL12 A allele was associated with higher blast cell count in the peripheral blood but not in the bone marrow. It could be associated with lower secretion of SDF-1, a hypothesis supported by the lower SDF-1 level described in the plasma of normal homozygous 801A subjects and in the stromal layer supernatants of long-term marrow cultures established from G801A carrier patients suffering from lymphoid malignancy [31] . This decreased production of SDF-1 might explain the increased capability of malignant cells to egress from the bone marrow microenvironment [21] .
As regards extramedullary tissue infiltration in AML patients, the frequency of splenomegaly was 47.4% in heterozygous genotype (A/G) while it was 52.6% in wild genotype (G/G). This was in agreement with Ponziani et al. [28] where splenomegaly was found in 41% of heterozygous genotype and 59% of wild genotype. On the other hand Abd El-Rahman et al. and Dommange et al. [21, 29] reported a slightly higher percentage of extramedullary tumor sites. In the present study no significance difference was found between CXCL12 genotype groups as regards the presence of splenomegaly in contrast to other investigators [21, 29] . The presence of a slightly higher percentage of organomegaly in CML patients carrying the CXCL12 A allele may be explained by cross-talk between p210 BCR-ABL and the CXCR4 pathway which results in disrupted signaling and chemotaxis in response to CXCL12 [32] . It was furthermore reported that leukemic CD34 + cells in CML patients display reduced chemotaxis to CXCL12 when compared with normal CD34 + cells [33] [34] [35] , which is due to deregulated CXCR4 signaling caused by cross-talk between the BCR/ABL oncoprotein and CXCR4 through the Src-related kinase Lyn [36] .
CONCLUSION
The present work suggests that SDF-1 polymorphism may be a step toward understanding the extramedullary malignant cell dissemination and homing to the bone marrow and which is considered the primary site for minimal residual disease in myeloid leukemia. However, our data do not stand in favor of the role of CXCL12 G801A polymorphism genotyping in extramedullary dissemination of blast cells but yet it was a step in the investigation of blast dissemination and homing of leukemic cells.
